Review
Scar wars: is TGFβ the phantom menace in scleroderma?
Andrew Leask

Division of Oral Biology and Department of Physiology and Pharmacology, CIHR Group in Skeletal Development and Remodeling, Division of Oral Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, Dental Sciences Building, London, ON N6A 5C1, Canada

Corresponding author: Andrew Leask, Andrew.Leask@schulich.uwo.ca

Abstract

The autoimmune disease scleroderma (systemic sclerosis (SSc)) is characterized by extensive tissue fibrosis, causing significant morbidity. There is no therapy for the fibrosis observed in SSc; indeed, the underlying cause of the scarring observed in this disease is unknown. Transforming growth factor-β (TGFβ) has long been hypothesized to be a major contributor to pathological fibrotic diseases, including SSc. Recently, the signaling pathways through which TGFβ activates a fibrotic program have been elucidated and, as a consequence, several possible points for anti-fibrotic drug intervention in SSc have emerged.

Introduction

During normal connective tissue repair, fibroblasts proliferate and migrate into the wound, where they synthesize, adhere to and contract extracellular matrix (ECM) proteins, resulting in wound closure. It has been proposed that a failure to down-regulate the normal tissue repair program causes the pathological scarring characterizing fibrotic diseases [1,2]. Fibrotic disease can affect individual organs, such as the kidney, liver, pancreas or lung, or be systemic, affecting all organs [1-5]. In its most severe forms, fibrosis results in organ failure and death. The systemic autoimmune disease scleroderma (systemic sclerosis (SSc)) possesses a significant fibrotic component; indeed, pulmonary fibrosis is the cause of the high mortality observed in SSc [6]. Identifying targets around which to base selective, anti-fibrotic therapies is, therefore, essential.

The fundamental mechanism underlying the excessive scarring observed in SSc is unknown. However, fibrosis is generally considered to arise from a failure to down-regulate the normal tissue repair program [2]. One of the major cytokines induced during the tissue repair is transforming growth factor (TGF)-β [7]. As TGFβ induces fibroblasts to synthesize and contract ECM, this cytokine has long been believed to be a central mediator in wound healing and fibrotic responses, including SSc [5]; however, the exact contribution of TGFβ to the fibrotic phenotype of SSc is unclear. Furthermore, as TGFβ plays many roles in normal physiology, including as a suppressor of the immune response and epithelial proliferation, broadly targeting TGFβ signaling for the treatment of disease is anticipated to be problematic [8]. Thus, much interest exists, from both clinical and pharmaceutical points of view, in identifying methods of intervening within the TGFβ signaling cascade in such a fashion that the pro-fibrotic aspects of TGFβ signaling are blocked but other TGFβ-dependent processes are unaltered.

This review critically evaluates the evidence supporting the notion that TGFβ is a critical mediator of fibrogenesis in SSc, and assesses whether there are intervention points within the TGFβ cascade that might be appropriate targets around which to base selective anti-fibrotic therapies to treat SSc.

Transforming growth factor-β signaling

There are three TGFβ isoforms, TGFβ1, TGFβ2 and TGFβ3, which are synthesized as latent precursors in complex with latent TGFβ-binding proteins (for reviews, see [8-11]). When these binding proteins are removed by proteolysis, TGFβ is activated. The 'TGFβ activators' include the proteases plasmin, matrix metalloproteinase (MMP)-2 and MMP-9, thrombospondin-1, and the integrin $\alpha_v\beta_6$. Active TGFβ binds to a heteromeric receptor complex, consisting of one TGFβ type I and one TGFβ type II receptor. In the presence of TGFβ ligand, the TGFβ receptor I kinase phosphorylates the receptor-activated Smads (R-Smads), Smad2 and Smad3, which are then able to bind the common mediator Smad, Smad4, and translocate into the nucleus (Figure 1). The Smad3-Smad4 pair binds promoters at the Smad consensus sequence, CAGAC [12]. Smad2, on the other hand, is not believed to bind DNA directly, but rather requires a nuclear DNA-binding protein of the family Fast (Fast-1) to bind DNA

CTGF = connective tissue growth factor; ECM = extracellular matrix; EDA = extra domain A; ET = endothelin; ETA = endothelin receptor A; ETB = endothelin receptor B; FAK = focal adhesion kinase; MMP = matrix metalloproteinase; SSc = systemic sclerosis; SMA = smooth muscle actin; TGF = transforming growth factor.

Figure 1

Transforming growth factor (TGF)β signaling generally occurs through TGFβ type I and type II receptors and Smads. TGFβ binds to the TGFβ type I and type II receptors. The type I receptor contains kinase activity, and phosphorylates receptor-activated Smads, Smad2 and Smad3, which dimerize with Smad4. The resultant complex migrates into the nucleus to activate target gene expression. TGFβ induces the inhibitory Smads, Smad6 and Smad7, which block TGFβ receptor type I-dependent Smad 2/3 activation.

[13]. The ability of this complex to activate transcription depends on the ability of Smads to recruit common transcriptional cofactors, such as p300, and basal transcription factors, which vary depending on the promoter of interest. A third group of Smad proteins, the inhibitory Smads Smad6 or Smad7, prevents R-Smad phosphorylation and subsequent nuclear translocation of R-Smad-Smad4 heterocomplexes; it appears that Smad7 competes with Smad2 and Smad3 for binding to the TGFβ type I receptor [14]. TGFβ also induces Smad7 through a Smad3 and Smad4-dependent mechanism, suggesting that TGFβ can suppress its own action via the induction of Smad7 [15] (Figure 1). Overall, the Smads mediate immediate-early responses to TGFβ, and their activity is tightly controlled.

In addition to the Smads, TGFβ also causes the activation of other signaling pathways, for example the mitogen activated protein kinase cascades. These cascades are not required for Smad activity *per se*, but are required for the activation of basal transcription factors and potentially for the enhancement of TGFβ responses [10,16-18] (Figure 2). Thus, transcriptional responses to TGFβ generally require the type I and type II TGFβ receptors and the Smads (Figure 2). Specificity of transcriptional responses to TGFβ rely, therefore, on ancillary signaling pathways induced by TGFβ, and the basal transcription factors recruited to the promoter (Figure 2).

The evidence for TGFβ as a pro-fibrotic cytokine in systemic sclerosis

Evidence supporting the contribution of TGFβ in fibrotic responses has principally been derived using acute *in vitro* or

in *vivo* models. For example, treatment of fetal wounds with TGFβ promotes wound closure and scarring [19,20]. In addition, injection of TGFβ, either directly subcutaneously or into metal chambers, results in enhanced deposition of ECM [20-22]. Furthermore, incisional rat wounds treated with anti-TGFβ antibodies or antisense oligonucleotides show a marked reduction in ECM synthesis and scarring [23,24]. Although TGFβ1 deficient mice display markedly reduced collagen deposition compared to control mice, such mice also show a severe wasting syndrome accompanied by a pronounced, generalized inflammatory response and tissue necrosis, resulting in organ failure and death [25,26]. These results are consistent with the fact that, as discussed above, TGFβ is pleiotropic and that broad targeting of TGFβ in humans is likely to have adverse side-effects. [8]. Indeed, resistance to the antiproliferative effects of TGFβ is a hallmark of cancer cells [27].

Addition of TGFβ ligand to cells or mice causes only a transient fibrotic response, which persists only as long as TGFβ ligand is present [22,28]. TGFβ does promote persistent fibrotic responses *in vivo*, but requires a cofactor, such as connective tissue growth factor (CTGF, CCN2) [22]. This notion that other factors are required to perpetuate fibrotic responses to TGFβ is supported by observations using materials derived from SSc patients. In dermal fibrotic lesions of scleroderma patients, elevated TGFβ levels exist at the leading edge of the forming scar tissue, but not within the established lesions [29]. In addition, elevated serum TGFβ levels are found only in some patients [30]. Finally, a recent report showed, paradoxically, that TGFβ levels in patients with diffuse SSc showed lower levels of active TGFβ in serum, relative to controls, and, moreover, active TGFβ levels correlated inversely with the severity of fibrosis [31]. These results may suggest, however, that TGFβ might be preferentially sequestered, and consumed, by the connective tissue in SSc [31]. The overexpression of type I collagen by cultured SSc fibroblasts, which produce neither elevated TGFβ levels nor increased latent TGFβ, is nevertheless reduced by neutralizing TGFβ antibodies or antisense RNA [32]. These results suggest that SSc fibroblasts show an enhanced response to endogenous TGFβ ligand. It is interesting to note, however, that an oral presentation at the 2004 International Scleroderma Meeting at Cambridge, UK, discussed a clinical safety trial using a neutralizing anti-TGFβ antibody in SSc patients. This trial showed that a neutralizing anti-TGFβ antibody showed neither an anti-fibrotic ability nor a toxic side-effect. However, as only one dose of antibody was used, it is difficult to evaluate from this unpublished study whether targeting TGFβ ligand may be an appropriate anti-fibrotic strategy in SSc.

A priori, the enhanced response to TGFβ in SSc fibroblasts may arise through an elevation in TGFβ receptor levels. Indeed, SSc fibroblasts possess increased levels of the signaling TGFβ type I receptor, relative to the TGFβ type II receptor [33]. As overexpression of TGFβ type I receptor in

Figure 2

Schematic diagram of general and gene-specific transforming growth factor (TGF)β signaling in fibroblasts. TGFβ binds to the TGFβ type I and type II receptors, activates Smad3, which activates target gene expression by binding the sequence CAGA. This pathway regulates virtually every TGFβ responsive gene in fibroblasts. Conversely, TGFβ can act with endothelin-1 (ET-1), connective tissue growth factor (CTGF) and extra domain A-fibronectin (EDA-FN) via the endothelin receptor A and B (ETA/B) receptors, syndecan 4 and integrins to activate ERK and focal adhesion kinase (FAK), which are required for target gene expression, in a promoter-specific fashion (for details see text).

normal fibroblasts increased basal collagen expression in a dose-dependent manner, it is conceivable that the over-expression of type I collagen observed in SSc fibroblasts may arise because of this defect [32]. Supporting the idea that TGFβ signaling through the TGFβ type I receptor contributes to the pathogenesis of SSc, the over-expression of type I collagen by SSc fibroblasts is blocked by a TGFβ type I receptor antagonist [34]. Similarly, the enhanced ECM contraction and adhesion observed in SSc fibroblasts depends on TGFβ type I receptor activity [34,35]. However, it should be pointed out that TGFβ type I receptor inhibition also reduced basal collagen synthesis, adhesion and contraction in normal and SSc fibroblasts, consistent with the notion that the contribution of TGFβ and TGFβ signaling to the phenotype of SSc fibroblasts may arise from an exaggeration of processes operating in normal fibroblasts [34,35]. Further complicating the issue, TGFβ type I receptor inhibition had no significant effect on the overexpression of CTGF or α-smooth muscle actin by SSc fibroblasts [34]. Collectively, these results suggest that signaling through the TGFβ receptors is likely to contribute to some aspects of SSc but not others. Finally, as discussed above, although these data strongly suggest that the TGFβ ligand-type I receptor axis contributes to the fibrotic phenotype in SSc, broad targeting of the type I TGFβ receptors is likely to be problematic in SSc as the type I receptor generally mediates TGFβ signaling [10]. Indeed, animals genetically deficient in TGFβ receptor type I die *in utero* and display severe vascular defects [36]. That said, the above data suggest that identifying a method of reducing the type I/type II receptor ratio to that of normal fibroblasts might be a viable method for selective anti-fibrotic drug intervention in SSc.

Smads in systemic sclerosis

In addition to implicating TGFβ ligand, acute *in vitro* and i*n vivo* models have strongly supported the role of Smad3 in fibrogenesis. Following incisional wounding, animals lacking Smad3 show accelerated wound healing, reduced granulation tissue formation, increased epithelialization, and reduced inflammation, possibly due to an impaired chemotactic response [37]. Smad 3-deficient mice display resistance to cutaneous fibrosis caused by radiation injury [38] or bleomycin [39]. Experiments using microarrays and western blot analyses have compared gene expression profiles of fibroblasts taken from adult *Smad3*⁻/⁻ and *Smad3*⁺/⁺ mice, and have shown that TGFβ was not able to induce transcription in *Smad3*⁻/⁻ fibroblasts, including the production of matrix and proadhesive proteins such as collagen and CTGF [40-42]. However, between four and six months of age, Smad3 mutant mice become moribund, with chronic inflammation and colorectal adenocarcinomas [43]. Smad 3 deficient mice also can develop degenerative joint disease resembling human osteoarthritis, as characterized by progressive loss of articular cartilage, decreased production of proteoglycans, and abnormally increased number of type X collagen-expressing chondrocytes in synovial joints [44]. These results strongly suggest that targeting Smad3 pharmacologically would be expected to have severe side-effects.

Within the context of SSc, leading edge SSc fibroblasts show activation of Smad3; in some studies, this activation has been shown to depend on TGFβ ligand, whereas other studies have shown this may be ligand independent [45, 46]. Although both type I collagen and CTGF are induced by TGFβ in a Smad-dependent fashion, the elevated activity of

the type I collagen promoter in SSc cells is dependent on the Smad element; however, the over-expression of CTGF is not [31,40]. Lesional SSc fibroblasts overexpress the TGFβ ancillary receptor endoglin in a fashion correlating with disease severity [47]. Endoglin, when overexpressed in fibroblasts, suppresses the ability of TGFβ to induce Smad activation [47]. These results suggest lesional SSc fibroblasts overexpress endoglin to block further Smad-dependent gene induction. In this regard, one report showed decreased levels of the inhibitory Smad7 in scleroderma fibroblasts [48], albeit in unaffected skin. Other studies showed no difference, or even an increase in Smad7 levels in SSc fibroblasts [40,45,49]. In one study, Smad7 was constitutively present on the TGFβ receptors [49]. The result of this defect is likely to be a bias away from Smad-dependent signaling in lesional scleroderma fibroblasts. Indeed, SSc fibroblasts are relatively non-responsive to exogenously added TGFβ ligand [50].

Collectively, the above observations reveal the complex role that TGFβ plays in mediating fibrogenesis, and seems to suggest that targeting generic TGFβ pathways (TGFβ ligand, receptors, Smads, p300) is likely to be problematic, not only due to the pleiotropic nature of these molecules, but also due to the complex possibly stage-specific ways that cells have of suppressing these responses. Thus, given the pleiotropic nature of TGFβ, it is preferable to target gene- or function-specific, as opposed to general, pathways mediating TGFβ signaling. Therefore, much recent interest has focused on identifying mediators of TGFβ signaling affecting fibrosis-specific, or fibrosis-selective, endpoints.

Gene-specific pathways contributing to fibrogenesis in SSc

It is likely, then, that targeting the ability of TGFβ to induce specific pathways or genes will be of benefit in generating selective therapies in SSc. In fibroblasts, TGFβ transiently activates the ras/MEK/ERK cascade, which is required for the induction of CTGF expression [16-18]. Intriguingly, in both mesangial cells and fibroblasts, TGFβ induction of a generic Smad3-responsive promoter occurs in the presence of either dominant negative ras or the mitogen activated protein kinase inhibitor U0126, indicating that the absolute requirement for the ras/MEK/ERK cascade in the induction of TGFβ-responsive genes seems to be restricted in a promoter-specific fashion [16-18]. The stable prostacyclin analog Iloprost, which alleviates symptoms of fibrosis *in vivo* and reduces CTGF expression and TGFβ-induced collagen deposition, acts at least in part by antagonizing the ras/MEK/ERK cascade via the elevation of cAMP [18]. Consistent with this notion, reduction in ERK reduces the overexpression of type I collagen, and the enhanced adhesive and contractile ability of SSc fibroblasts [35].

The ability of TGFβ to induce ERK is prevented in fibroblasts genetically deficient for the proteoglycan syndecan 4, and

small interfering RNA recognizing syndecan 4 reduces the elevated ERK activation seen in SSc fibroblasts [35]. Syndecan 4 knockout mice appear phenotypically normal, but show reduced tissue repair responses, indicating that syndecan 4 is selectively required for the tissue repair program [51]. Thus, although broadly targeting MEK/ERK inhibition would be expected to have severe side-effects due to the involvement of this signaling pathway in many processes, targeting syndecan 4 is likely to be of benefit in selectively targeting fibrogenic responses (Figure 2). Syndecan 4 is a receptor for fibronectin, and is a focal adhesion component and is required for focal adhesion kinase (FAK) phosphorylation [52]. Recent data have suggested that FAK and the extra domain A (EDA) form of fibronectin mediate the ability of TGFβ to induce α-smooth muscle actin (α-SMA) [53,54]. Anti-EDA antibody or recombinant EDA protein suppresses α-SMA induction, but not that of other TGFβ-responsive genes [54]. Consistent with this notion, elevated FAK phosphorylation is observed in SSc fibroblasts [55]. Over-expression of a kinase-defective FAK mutant reduced α-SMA expression in SSc fibroblasts [55]. These results emphasize the notion that although the generic TGFβ signaling pathways may not be suitable targets for selective drug intervention in SSc, examining how individual target genes are selectively induced is likely to provide clues as to how to interfere with appropriate pathways with drugs. Indeed, targeting adhesive signaling might be of benefit in combating SSc (Figure 2).

Synergy between TGFβ and other cytokines.

As mentioned above, in addition to signaling pathways directly induced by TGFβ ligand, there is substantial evidence for synergy between TGFβ and other extracellular ligands in driving fibrogenic responses. These other ligands include CTGF and endothelin (ET)-1.

Connective tissue growth factor (CTGF, CCN2)

CTGF, a member of the CCN family of proteins [56,57], is induced by TGFβ in normal fibroblasts, but not in keratino-cytes, through Smads, Ets-1, protein kinase C and ras/MEK/ERK [16-18,40,58]. CTGF is constitutively expressed by mesenchymal cells in development, and by kidney mesangial cells and endothelial cells and is characteristically over-expressed in fibrotic disease, including SSc, in a fashion correlating with severity of fibrosis [59,60]. CTGF and TGFβ act together to promote sustained fibrosis in rodents [22]. Consistent with this notion, CTGF-deficient embryonic fibroblasts can respond to TGFβ through the Smad pathway, but show impaired induction of adhesive signaling, as visualized by the induction of FAK and Akt and the induction of α-SMA and type I collagen [61]. These results are consistent with the notion that CTGF executes its functions through integrins [62-64], and with a previous hypothesis that CTGF is a mediator of pro-fibrotic responses to TGFβ [65]. However, what is surprising is that the lack of responses observed in CTGF-deficient embryonic fibroblasts were due

to the absence of basal CTGF expression [61]. CTGF was required for TGFβ to induce cell adhesion to fibronectin and type I collagen [61]. These results suggest that CTGF acts as a cofactor of TGFβ to induce adhesive signaling in cells that are already activated and undergoing tissue remodeling (e.g., embryonic and fibrotic fibroblasts), and also that targeting basal CTGF expression, which is independent of the TGFβ response element and is not blocked by inhibition of the TGFβ type I receptor [33,38], might be of benefit in SSc [66,67].

Endothelin-1

ET-1 is normally produced by endothelial cells, but is over-expressed by SSc fibroblasts [68]. When added to fibroblasts, ET-1 independently induces a program of ECM synthesis and contraction [68,69], and can act synergistically with TGFβ [70,71]. Blockade of the endothelin receptors with a dual endothelin receptor A and B (ETA/B) antagonist significantly reduces α-SMA overexpression and ECM contraction by SSc fibroblasts [68]. As addition of a TGFβ receptor inhibitor to SSc fibroblasts does not affect α-SMA expression but does impact ECM contraction [34,35], these results suggest that ET-1 acts additively and cooperatively with TGFβ. Significantly, and in contrast to TGFβ receptor antagonism [34,35], ETA/B receptor blockade does not block basal fibroblast activity [68]. ET-1 induces expression of target genes through Akt and ras/MEK/ERK [68,69]. The ET-1 response element in the CTGF promoter is distinct from the TGFβ response element [16,17], and the ET-1 response element, but not the TGFβ response element, is required for the over-expression of CTGF in SSc [40]. Collectively, these data support the notion that TGFβ and ET-1 act together to promote fibrogenesis in SSc through differing yet complementary pathways (Figure 1). The ETA/B receptor antagonist bosentan is currently used clinically to treat pulmonary hypertension and the formation of new digital ulcers in SSc patients [72,73]. Thus ETA/B receptor antagonism is well tolerated in patients, and is likely, therefore, to be of clinical benefit in alleviating at least one aspect of fibrosis in SSc, namely that of the persistently activated fibroblast. A one-year, unpublished clinical trial in which the efficacy of bosentan at alleviating pulmonary fibrosis in SSc patients was tested was recently concluded, and was negative. However, a non-fibrotic endpoint (a walk-test) was used to evaluate the efficacy of bosentan on overall lung function. Moreover, the length of the clinical trial may have been too short to properly evaluate whether bosentan has an anti-fibrotic effect. For final conclusions to be drawn the published results are needed. Thus it remains unclear whether bosentan may be effective in suppressing fibrosis in patients.

Conclusion

TGFβ induces matrix synthesis in fibroblasts and fibrotic responses *in vivo* and *in vitro*. The majority of the studies conducted thus far has measured acute responses to TGFβ, but suggest that TGFβ alone is insufficient for fibrogenesis. Furthermore, genetic and pharmacological studies have suggested that broad targeting of general TGFβ signaling pathways, although perhaps of benefit in suppressing aspects of the SSc phenotype, might be problematic for treating SSc due to the pleiotropic nature of TGFβ. The past several years have led to an appreciation that additional pathways and receptors to the generic, universal TGFβ/TGFβ type I and type II receptor/Smad axis are involved with fibrogenic responses to TGFβ, including syndecan 4, EDA fibronectin, ras/MEK/ERK, FAK, CTGF and ET-1 (Figure 2). By manipulating these ancillary pathways, selective anti-fibrotic effects might be achieved, for example, by identifying inhibitors that block induction of fibrotic genes but leave other pathways intact.

Competing interests

The author declares that they have no competing interests.

References

1. Eckes B, Zigrino P, Kessler D, Holtkotter O, Shephard P, Mauch C, Krieg T: **Fibroblast-matrix interactions in wound healing and fibrosis.** *Matrix Biol* 2000, **19:**325-332.
2. Gabbiani G: **The myofibroblast in wound healing and fibro-contractive diseases.** *J Pathol* 2003, **200:**500-503.
3. Bedossa P, Paradis V: **Liver extracellular matrix in health and disease.** *J Pathol* 2003, **200:**504-515.
4. Fogo AB: **Mesangial matrix modulation and glomerulosclerosis.** *Exp Nephrol* 1999, **7:**147-159.
5. LeRoy EC, Trojanowska MI, Smith EA: **Cytokines and human fibrosis.** *Eur Cytokine Netw* 1990, **1:**215-219.
6. Steen VD, Medsger TA Jr: **Severe organ involvement in systemic sclerosis with diffuse scleroderma.** *Arthritis Rheum* 2000, **43:**2437-2444.
7. Kane CJ, Hebda PA, Mansbridge JN, Hanawalt PC: **Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing.** *Cell Physiol* 1991, **148:**157-173.
8. McCartney-Francis NL, Frazier-Jessen M, Wahl SM: **TGF-beta: a balancing act.** *Int Rev Immunol* 1998, **16:**553-580.
9. Massague J: **TGF-beta signal transduction.** *Annu Rev Biochem* 1998, **67:**753-791.
10. Leask A, Abraham DJ: **TGF-beta signaling and the fibrotic response.** *FASEB J* 2004, **18:**816-827.
11. Roberts AB: **TGF-beta signaling from receptors to the nucleus.** *Microbes Infect* 1999, **1:**1265-1273.
12. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE: **Human Smad3 and Smad4 are sequence-specific transcription activators.** *Mol Cell* 1998, **1:**611-617.
13. Liu B, Dou CL, Prabhu L, Lai E: **FAST-2 is a mammalian winged-helix protein which mediates transforming growth factor beta signals.** *Mol Cell Biol* 1999, **19:**424-430.
14. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P: **Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.** *Nature* 1997, **389:**631-635.
15. von Gersdorff G, Susztak K, Rezvani F, Bitzer M, Liang D, Bottinger EP: **Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta.** *J Biol Chem* 2000, **275:**11320-11326.
16. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A: **CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC.** *Kidney Int* 2002, **62:**1149-1159.
17. Leask A, Holmes A, Black CM, Abraham DJ: **CTGF gene regula-**

tion: requirements for its induction by TGFβ in fibroblasts. *J Biol Chem* 2003, **278:**13008-13015.

18. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A: **Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway.** *FASEB J* 2002, **16:**1949-1951.
19. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF: **Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta.** *Science* 1987, **237:**1333-1336.
20. Lin RY, Sullivan KM, Argenta PA, Meuli M, Lorenz HP, Adzick NS: **Exogenous transforming growth factor-beta amplifies its own expression and induces scar formation in a model of human fetal skin repair.** *Ann Surg* 1995, **222:**146-154.
21. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR: **Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP.** *FASEB J* 1999, **13:**1774-1786.
22. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K: **Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model.** *J Cell Physiol* 1999, **181:**153-159.
23. Shah M, Foreman DM, Ferguson MW: **Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents.** *J Cell Sci* 1994, **107:**1137-1157.
24. Cordeiro MF, Mead A, Ali RR, Alexander RA, Murray S, Chen C, York-Defalco C, Dean NM, Schultz GS, Khaw PT: **Novel anti-sense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome** *Gene Ther* 2003, **10:**59-71.
25. Kulkarni AB, Karlsson S: **Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease.** *Am J Pathol* 1993, **143:**3-9.
26. Bottinger EP, Letterio JJ, Roberts AB: **Biology of TGF-beta in knockout and transgenic mouse models.** *Kidney Int* 1997, **51:**1355-1360.
27. Reiss M: **TGF-beta and cancer.** *Microbes Infect* 1999, **1:**1327-1347.
28. McWhirter A, Colosetti P, Rubin K, Miyazono K, Black C: **Collagen type I is not under autocrine control by transforming growth factor-beta 1 in normal and scleroderma fibroblasts.** *Lab Invest* 1994, **71:**885-894.
29. Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S: **Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma.** *J Dermatol Sci* 1999, **21:**13-22.
30. Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MI, Brenchley PE: **Plasma TGF beta in systemic sclerosis: a cross-sectional study.** *Ann Rheum Dis* 1994, **53:**763-767.
31. Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP: **Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.** *Rheumatology* 2005, **44:**1518-1524.
32. Ihn H, Yamane K, Kubo M, Tamaki K: **Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors.** *Arthritis Rheum* 2001, **244:**474-478.
33. Pannu J, Gore-Hyer E, Yamanaka M, Smith EA, Rubinchik S, Dong JY, Jablonska S, Blaszczyk M, Trojanowska M: **An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.** *Arthritis Rheum* 2004, **50:**1566-1577.
34. Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ: **ALK5 (TGFβ receptor type I) signaling contributes to the fibrotic phenotype of scleroderma fibroblasts.** *Arthritis Rheum* 2006, **54:**1309-1316.
35. Chen Y, Shiwen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A: **Matrix contraction by dermal fibroblasts requires TGFbeta/ALK5, heparan sulfate containing proteoglycans and MEK/ERK: Insights into pathological scarring in chronic fibrotic disease.** *Am J Pathol* 2005, **167:**1699-1711.

36. Larsson J, Goumans M, Sjöstrand LJ, van Rooijen MA, Ward D, Levéen P, Xu X, ten Dijke P, Mummery CL, Karlsson S: **Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice.** *EMBO J* 2001, **20:**1663-1673.
37. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB: **Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response.** *Nat Cell Biol* 1999, **1:**260-266.
38. Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arab-shahi A, Major C, Deng C, Russo A, Mitchell JB, Roberts AB: **Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation.** *Am J Pathol* 2002, **160:**1057-1068.
39. Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, Wang XJ, DiPietro LA, Varga J: **Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.** *Am J Pathol* 2004, **165:**203-217.
40. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A: **CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling.** *J Biol Chem* 2001, **276:**10594-10601.
41. Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, Pavlidis P, Kucherlapati R, Roberts AB, Bottinger EP: **Hierarchical model of gene regulation by transforming growth factor beta.** *Proc Natl Acad Sci USA* 2003, **100:**10269-10274.
42. Verrecchia F, Chu ML, Mauviel A: **Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach.** *J Biol Chem* 2001, **276:**17058-17062.
43. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C: **Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta.** *EMBO J* 1999, **18:**1280-1291.
44. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS: **The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis.** *J Bone Miner Res* 2001, **16:**1754-1764.
45. Mori Y, Chen SJ, Varga J: **Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts.** *Arthritis Rheum* 2003, **48:**1964-1978.
46. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K: **Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts.** *Am J Pathol* 2005, **166:**1451-1463.
47. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, Chen Y, Venstrom K, Dou X, Ponticos M, *et al.:* **Dysregulation of transforming growth factor beta signaling in scleroderma: over-expression of endoglin in cutaneous scleroderma fibroblasts.** *Arthritis Rheum* 2002, **46:**1857-1865.
48. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, ten Dijke P, White B, Wigley FM, Goldschmidt-Clermont PJ: **Deficient Smad7 expression: a putative molecular defect in scleroderma.** *Proc Natl Acad Sci USA* 2002, **99:**3908-3913.
49. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K: **Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.** *J Clin Invest* 2004, **113:**253-264.
50. Kikuchi K, Hartl CW, Smith EA, LeRoy EC, Trojanowska M: **Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: insensitivity to TGF beta 1 stimulation.** *Biochem Biophys Res Commun* 1992, **187:**45-50.
51. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M, Goetinck P: **Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.** *J Clin Invest* 2001, **107:**R9-R14.
52. Wilcox-Adelman SA, Denhez F, Goetinck PF: **Syndecan-4 modulates focal adhesion kinase phosphorylation.** *J Biol Chem* 2002, **277:**32970-32977.
53. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, Horowitz JC, Day RM, Thomas PE: **Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase.** *J Biol Chem* 2003, **278:**12384-12389.
54. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G: **The fibronectin domain ED-A is crucial for**

myofibroblastic phenotype induction by transforming growth factor-beta1. *J Cell Biol* 1998, **142:**873-881.

55. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K: **Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts.** *J Invest Dermatol* 2005, **124:**886-892.

56. Bork P: **The modular architecture of a new family of growth regulators related to connective tissue growth factor.** *FEBS Lett* 1993, **327:**125-130.

57. Perbal B: **CCN proteins: multifunctional signalling regulators.** *Lancet* 2004, **363:**62-64.

58. Van Beek JP, Kennedy L, Rockel JS, Bernier SM, Leask A: **The induction of CCN2 by TGFbeta1 involves Ets-1.** *Arthritis Res Ther* 2006, **8:**R36.

59. Dziadzio M, Usinger W, Leask A, Abraham D, Black CM, Denton C, Stratton R: **N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma.** *QJM* 2005, **98:**485-492.

60. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, *et al.*: **Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy.** *Diabetes Care* 2004, **27:**1164-1170.

61. Shi-Wen X, Stanton L, Kennedy L, Pala D, Chen Y, Howat SL, Renzoni EA, Carter DE, Bou-Gharios G, Stratton R, *et al.*: **CCN2 is necessary for adhesive responses to TGFbeta 1 in embryonic fibroblasts.** *J Biol Chem* 2006, **281:**10715-10726.

62. Chen Y, Abraham DJ, Shi-Wen X, Pearson JD, Black CM, Lyons KM, Leask A: **CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin.** *Mol Biol Cell* 2004, **15:**5635-5646.

63. Babic AM, Chen CC, Lau LF: **Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo.** *Mol Cell Biol* 1999, **19:**2958-2966.

64. Gao R, Brigstock DR: **Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan.** *J Biol Chem* 2004, **279:**8848-8855.

65. Grotendorst GR: **Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts.** *Cytokine Growth Factor Rev* 1997, **8:**171-179.

66. Leask A, Denton, CP and Abraham DJ: **Insights into the molecular mechanism of sustained fibrosis: The role of connective tissue growth factor in scleroderma.** *J Invest Dermatol* 2004, **122:**1-6.

67. Takehara K: **Hypothesis: pathogenesis of systemic sclerosis.** *Rheumatol*ogy 2003, **30:**755-759.

68. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, *et al.*: **Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.** *Mol Biol Cell* 2004, **15:**2707-2719.

69. Shi-wen X, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, Bou-Gharios G, Denton CP, du Bois RM, Black CM, *et al.*: **Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK.** *J Biol Chem* 2004, **279:**23098-23103.

70. Shephard P, Hinz B, Smola-Hess S, Meister JJ, Krieg T, Smola H: **Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes.** *Thromb Haemost* 2004, **92:**262-274.

71. Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T: **Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1.** *FEBS J* 2005, **272:**6297-6309.

72. Denton CP, Black CM: **Pulmonary hypertension in systemic sclerosis.** *Rheum Dis Clin North Am* 2003, **29:**335-349, vii.

73. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, *et al.*: **Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.** *Arthritis Rheum* 2004, **50:**3985-3993.